Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab for Immune Activation in Schizophrenia
NCT07615075Phase 4Not yet recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
A Phase 4 trial of mirikizumab in schizophrenia, schizoaffective disorder, sponsored by University of Maryland, Baltimore. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
mirikizumab
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT07615075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07615075.